Company: REVB
Filing Date: 2025-06-04
Form Type: 8-K
Source: 0000950170-25-081604
Chunk: 0

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-06-04
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive Agreement.

On May 28, 2025, Revelation Biosciences, Inc., (the “ Company”), entered into a placement agency agreement (the “ Placement Agency Agreement”) with Roth Capital Partners, LLC (the “ Placement Agent”) and a securities purchase agreement (the “ Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “ Public Offering”), of (i) 675,000 shares of its common stock, par value $0.001 per share (the “ Common Stock”) and pre-funded warrants to purchase 2,965,000 shares of Common Stock (the “ Pre-Funded Warrants”) and (ii) accompanying warrants to purchase up to 14,560,000 shares of Common Stock (the “ Class H Common Stock Warrants”) at a combined offering price of $1.10 per share of Common Stock and associated Class H Common Stock Warrants, or $1.09 per Pre-Funded Warrant and associated Class H Common Stock Warrants, resulting in gross proceeds of approximately $4.0 million. The Public Offering closed on May 29, 2025. Subsequent to the closing all Pre-Funded Warrants were exercised.

The Class H Common Stock Warrants have an exercise price of $1.10 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The exercise price is separately subject to reduction in the event of certain future dilutive issuances of shares of Common Stock by the Company, including pursuant to common stock equivalents and convertible or derivative securities, or in the event of a reverse stock split. The Pre-Funded Warrants do not expire and have an exercise price of $0.0001 per share. The Pre-Funded Warrants were sold to purchasers whose purchase of shares of Common Stock in the Public Offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of the Company’s outstanding Common Stock immediately following the consummation of the Public Offering, in lieu of shares of Common Stock.

Each of the Placement Agency Agreement and Purchase Agreement contained representations, warranties and covenants made by the Company that are customary for transactions of this type. In addition, pursuant to the terms of the Purchase Agreement, the Company and its executive officers and directors have agreed not to, subject